Show simple item record

dc.contributor.authorPérez Trallero, Emilio
dc.contributor.authorTamayo, Esther
dc.contributor.authorMontes, Milagrosa
dc.contributor.authorGarcía Arenzana, José M.
dc.contributor.authorIriarte Campo, Victor
dc.date.accessioned2024-02-07T21:09:24Z
dc.date.available2024-02-07T21:09:24Z
dc.date.issued2011-04-28
dc.identifier.citationAntimicrobial Agents and Chemotherapy 55(5) : 2406-2408 (2011)
dc.identifier.issn0066-4804
dc.identifier.issn1098-6596
dc.identifier.urihttp://hdl.handle.net/10810/64760
dc.description.abstractRetapamulin in vitro activity against 400 Streptococcus pyogenes clinical isolates obtained from skin, pharynx, ear fluid, and blood samples recovered from 2007 to 2009 was studied. The isolates belonged to 26 different emm types, including isolates nonsusceptible to erythromycin (n=187), tetracycline (n=99), ciprofloxacin (n=59), and bacitracin (n=43). Results were compared to the activities of 16 other antibiotics for topical and systemic use. Retapamulin MICs ranged from <0.015 to 0.12 ug/ml, showing the highest intrinsic activity among the topical antimicrobial drugs studied.es_ES
dc.language.isoenges_ES
dc.publisherASM
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.titleIn vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolateses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2011 American Society for Microbiology*
dc.relation.publisherversionhttps://journals.asm.org/doi/10.1128/aac.01665-10
dc.identifier.doi/10.1128/aac.01665-10
dc.departamentoesInmunología, Microbiología y Parasitología
dc.departamentoeuInmunologia, Mikrobiologia eta Parasitologia


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record